Sunrise advantage: morning immunotherapy linked to longer survival in lung cancer

A randomized study in 210 patients with non-small-cell lung cancer found that receiving the first immunotherapy dose before 3 p.m. significantly improved outcomes compared with later dosing: about 11.3 months progression-free survival versus 5.7 months and roughly 45% alive versus 15% at follow-up, with morning treatment also showing more cancer-killing T cells. Experts caution that replication is needed, though a confirmatory trial is underway; the work was published in Nature Medicine.